RESUMO
The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the animal reflux-inflammation models for Barrett's esophagus and esophageal adenocarcinoma; genomic/epigenomic analyses; eflornithine-based combinations; the molecular derangements that promote neoplastic transformation; the role of COX-2 inhibitors, proton pump inhibitors, and phase II trials in Barrett's adenocarcinoma; statins in chemoprevention and treatment of esophageal cancer; and biomarkers as potential targets in Barrett's adenocarcinoma.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias Esofágicas/diagnóstico , Neoplasias Esofágicas/prevenção & controle , Animais , Esôfago de Barrett/diagnóstico , Esôfago de Barrett/metabolismo , Esôfago de Barrett/prevenção & controle , Biomarcadores Tumorais/metabolismo , Transformação Celular Neoplásica/metabolismo , Inibidores de Ciclo-Oxigenase 2/uso terapêutico , Eflornitina/uso terapêutico , Neoplasias Esofágicas/metabolismo , Refluxo Gastroesofágico/diagnóstico , Refluxo Gastroesofágico/metabolismo , Refluxo Gastroesofágico/prevenção & controle , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Paris , Inibidores da Bomba de Prótons/uso terapêuticoRESUMO
The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on translational research on Barrett's esophagus that address evidence for genetic instability in esophageal cancer; the role of microsatellite instability; the use of histologic and serum Doublecortin-like kinase 1 expression for progression of Barrett's esophagus to adenocarcinoma; the oxidative stress in Barrett's tumorigenesis; the genomic alterations in esophageal cancer; in vivo modeling in Barrett's esophagus; epigenetic and transcriptional regulation in Barrett's esophagus and esophageal adenocarcinoma; and normal and disordered regeneration in Barrett's esophagus.